Back to Scientific and Special Advisors

David Weiner, MD - Executive Committee
Senior Medical Director
Neurology Global Development Unit
EMD Serono Inc.
Rockville, Massachusetts

David Weiner received his medical degree from the State University of New York at Buffalo. He was a National Institutes of Health/Howard Hughes Medical Institute Research Scholar in the Laboratory of Molecular Biology at the National Institutes of Neurological Disorders and Stroke (NINDS) in Bethesda. He trained in neurology at Cornell New York Hospital/Memorial Sloan Kettering Cancer Center, and was a post-doctoral fellow in the Molecular Neuropharmacology Laboratories at the University of Vermont. Dr. Weiner held an active clinical and teaching position in the University of California San Diego Department of Neurosciences, where he was most recently an Adjunct Associate Clinical Professor in Neurology.
Dr. Weiner has worked, both in the pre-clinical and clinical arena, on the discovery and development of novel small molecule therapeutics for human neuropsychiatric disease. He worked at ACADIA Pharmaceuticals Inc. from 1997-2006, where he held various positions including Head of Target Validation and Medical Director-CNS. His research group was involved in the characterization of g-protein coupled receptor targets, as well as studies defining the mechanisms of action of known and experimental drugs. As Medical Director, he fostered the early development (pre-clinical thru Phase 2) of Pimavanserin (ACP-103) for psychosis in Parkinson’s Disease, as well as Pimavanserin and n-desmethylclozapine (ACP-104) for the treatment of Schizophrenia. He has recently joined EMD Serono, where his responsibilities include medical leadership of the development (Phase 3) of Safinamide in Parkinson’s disease.